
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Fidaxomicin is a pharmaceutical for the treatment of difficile-associated diarrhea (CDAD), indicated for adult and pediatric patients aged 6 months and older. CDAD is a gastrointes···【more】
Article source:Captain MedicineRelease date:2024-07-30Recommended:545
fidaxomicin, a pharmacological agent renowned for its efficacy against Clostridium difficile infection, operates by impeding the metabolic pathways of the bacterium, thus inhibitin···【more】
Article source:Captain MedicineRelease date:2024-07-30Recommended:520
Fidaxomicin is a pharmaceutical agent specifically designed to combat infections caused by Clostridium difficile. Prior to initiating treatment with Fidaxomicin, patients are advis···【more】
Article source:Captain MedicineRelease date:2024-07-30Recommended:450
Sotorasib, a targeted therapeutic agent for advanced non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C mutation, exerts its efficacy by specifically inhibiting th···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:570
Sotorasib, also known as Lumakras, is a targeted drug designed for patients with NSCLC carrying the KRAS G12C gene mutation. This medication inhibits the activity of the KRAS G12C ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:570
Sotorasibas a targeted therapeutic agent, is hailed as a milestone advancement in the medical field. As one of the pioneering small molecule inhibitors successfully targeting KRAS ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:525
Sotorasib is a targeted therapy for patients with advanced NSCLC with KRAS p.G12C mutations.KRAS geneis a key regulator during cell growth and division, when the p.G12C mutation oc···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:596
Sotorasib represents a groundbreaking targeted therapy that has exhibited remarkable efficacy in combatting non-small cell lung cancer (NSCLC), particularly among individuals harbo···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:546
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:610
Sotorasib emerges as a groundbreaking targeted therapy for non-small cell lung cancer (NSCLC) individuals carrying KRAS G12C alterations. Sotorasib exerts its therapeutic efficacy ···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:538
Sotorasib, a small molecule inhibitor targeting the KRAS G12C gene mutation in non-small cell lung cancer (NSCLC), has garnered significant attention since its debut. Its distincti···【more】
Article source:Captain MedicineRelease date:2024-07-09Recommended:509
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:8522025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:10492024-09-07
Recently, Lao Lucius Pharmaceutical (Lucius Pharmaceuticals) issued a solemn statement regarding cou···【more】
Recommended:2982026-10-10
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended:4042026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended:5962026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended:5672026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended:4542026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended:6052026-31-07

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com

Name: Lucius

Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643